How signaling in the brain's striatum may drive Parkinson's symptoms
Striatal Trans-Synaptic Signaling Mechanism in Parkinsonism
['FUNDING_R01'] · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · NIH-11180248
This project looks at whether correcting a specific signaling connection between the thalamus and striatum could ease movement problems and anxiety in people with Parkinson's disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR (nih funded) |
| Locations | 1 site (COLLEGE STATION, UNITED STATES) |
| Trial ID | NIH-11180248 on ClinicalTrials.gov |
What this research studies
As someone with Parkinson's, it's helpful to know researchers are studying how certain brain connections between the thalamus and the striatum change as dopamine cells die. The team uses Parkinson's-like animal models and tools such as AAV gene delivery, optogenetics, and chemogenetics to manipulate the GluD1–Cbln1 synaptic complex at thalamostriatal synapses. They will track how these changes affect movement and anxiety-related behavior and map molecular changes at the synapse. Findings are intended to point to molecular targets that could be tested in future patient-focused therapies.
Who could benefit from this research
Good fit: People with Parkinson's disease, particularly those with early or mid-stage motor symptoms and accompanying anxiety, would be the most relevant candidates for future trials informed by this work.
Not a fit: Patients with very advanced neurodegeneration, atypical parkinsonism, or conditions not driven by thalamostriatal dysfunction may not benefit from interventions based on this pathway.
Why it matters
Potential benefit: If successful, this work could identify new molecular targets in the striatum that lead to therapies improving movement and non-motor symptoms in Parkinson's disease.
How similar studies have performed: Prior animal studies using optogenetic or chemogenetic control of parafascicular thalamus inputs have improved motor function in Parkinson's models, but targeting the GluD1–Cbln1 synaptic complex is a novel approach not yet tested in humans.
Where this research is happening
COLLEGE STATION, UNITED STATES
- TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR — COLLEGE STATION, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DRAVID, SHASHANK MANOHAR — TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
- Study coordinator: DRAVID, SHASHANK MANOHAR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.